Kattan et al developed a predictive model for evaluating a patient with renal cell carcinoma following nephrectomy. This can help identify patients who may require closer monitoring for recurrence and more aggressive therapy. The authors are from Memorial Sloan-Kettering Cancer Center in New York City.
Parameters:
(1) symptoms
(2) histology of the tumor
(3) tumor size in centimeters
(4) pathologic stage from 1997 TNM criteria
points for tumor size =
= 5 * (diameter of the tumor in centimeters)
Parameter |
Finding |
Points |
---|---|---|
symptoms |
local |
0 |
|
incidental |
0.6 |
|
systemic |
31.5 |
histologic type |
chromophobe |
0 |
|
papillary |
9 |
|
conventional clear cell |
39 |
pathologic stage |
pT1 |
0 |
|
pT2 |
19 |
|
pT3a |
7 |
|
pT3b |
31 |
|
pT3c |
31 |
where:
• The scheme described pathologic stages from P1 to P3c. After reviewing the TNM staging criteria the only matching parameter is the pathologic T stage (pT).
total number of points =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: > 200
• The higher the score the lower the chances of recurrence free survival.
Total Points |
Probability of 5 Year (60 Month) Tumor Free Survival |
---|---|
< 9 |
> 98% |
9 |
98% |
34 |
96% |
49 |
94% |
68 |
90% |
84 |
85% |
95 |
80% |
112 |
70% |
125 |
60% |
136 |
50% |
146 |
40% |
156 |
30% |
167 |
20% |
> 167 |
< 20% |
percent tumor free survival with 9 to 95 points =
= (-0.002183 * ((points)^2)) + (0.0222 * (points)) + 97.9218
percent tumor free survival with 95 to 167 points =
= (-0.003505 * ((points)^2)) + (0.06557 * (points)) + 105.9342
Purpose: To evaluate a patient with renal cell carcinoma following nephrectomy using the prognostic model of Kattan et al.
Specialty: Hematology Oncology, Surgery, general, Nephrology
Objective: severity, prognosis, stage
ICD-10: C64,